Pieris Pharmaceuticals (PIRS) Rating Increased to Hold at ValuEngine

Pieris Pharmaceuticals (NASDAQ:PIRS) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Friday.

A number of other brokerages have also recently issued reports on PIRS. HC Wainwright upped their target price on Pieris Pharmaceuticals from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, January 16th. BidaskClub upgraded Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Finally, William Blair initiated coverage on Pieris Pharmaceuticals in a report on Wednesday, January 17th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $10.00.

Pieris Pharmaceuticals (NASDAQ:PIRS) traded up $0.40 during trading hours on Friday, hitting $8.07. The stock had a trading volume of 1,021,865 shares, compared to its average volume of 546,775. The company has a market cap of $361.49, a P/E ratio of -10.91 and a beta of 1.57. Pieris Pharmaceuticals has a 1 year low of $1.88 and a 1 year high of $8.34.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative return on equity of 221.93% and a negative net margin of 321.83%. The firm had revenue of $3.93 million during the quarter, compared to the consensus estimate of $1.52 million. Pieris Pharmaceuticals’s revenue was up 400.3% on a year-over-year basis. sell-side analysts forecast that Pieris Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 147,635 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $5.70, for a total value of $841,519.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.05% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. State Street Corp purchased a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter worth approximately $2,377,000. Northern Trust Corp acquired a new stake in Pieris Pharmaceuticals during the 2nd quarter worth approximately $1,625,000. TIAA CREF Investment Management LLC acquired a new stake in Pieris Pharmaceuticals during the 2nd quarter worth approximately $649,000. Vanguard Group Inc. acquired a new stake in Pieris Pharmaceuticals during the 2nd quarter worth approximately $526,000. Finally, Strs Ohio lifted its holdings in Pieris Pharmaceuticals by 1,028.0% during the 4th quarter. Strs Ohio now owns 112,800 shares of the biotechnology company’s stock worth $851,000 after buying an additional 102,800 shares in the last quarter. Institutional investors own 50.77% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Pieris Pharmaceuticals (PIRS) Rating Increased to Hold at ValuEngine” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/04/pieris-pharmaceuticals-pirs-rating-increased-to-hold-at-valuengine.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply